Long COVID Treatments: Medication Safety and Current Research Gaps

Dealing with the aftermath of a virus is frustrating enough, but when those symptoms linger for years, it feels like you're fighting a ghost. For about 200 million people worldwide, this is the reality of Long COVID is a condition characterized by diverse, persistent symptoms that continue for weeks, months, or years following a SARS-CoV-2 infection, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC). Despite the massive scale of this crisis, we are still in a period of "trial and error." There isn't a single FDA-approved pill or injection specifically for this condition. Instead, doctors and researchers are repurposing existing drugs and hoping they work for a different set of problems.

The core struggle here is that Long COVID isn't one disease; it's a collection of over 200 different symptoms hitting multiple organs. How do you treat something when you aren't entirely sure what's causing it? While the RECOVER initiative is pumping over $1 billion into research, the road to a cure is littered with safety signals and failed trials. If you're looking at medications today, you're essentially looking at a map where half the landmarks are still being drawn.

The Current Medication Landscape: What's Being Tested?

Right now, the medical community is leaning heavily on drugs already approved for other conditions. The idea is simple: use a drug with a known safety record to see if it can dampen the inflammation or viral remnants causing PASC. One of the big players is Baricitinib, a Janus kinase (JAK) inhibitor. While it's great for rheumatoid arthritis, using it for Long COVID comes with a warning label. In arthritis trials, 10-20% of patients saw an increase in serious infections. There are also concerns about lymphoma and cardiovascular events. Researchers are currently running the REVERSE-LC trial to see if the benefits outweigh these risks for Long COVID patients, with results expected in late 2026.

Then there's the approach of using antivirals after the initial infection is gone. Nirmatrelvir/ritonavir, better known as Paxlovid, has had a bumpy road in research. One study from UCSF showed some improvement with a longer 15-day course, but a larger NIH trial found no significant difference between the drug and a placebo. Beyond that, the drug is notorious for a bitter taste and dangerous interactions with other medications due to how it affects the CYP3A4 enzyme in the liver.

For those focusing on metabolic or immune issues, Metformin has emerged as a front-runner. Originally a diabetes drug, a phase 3 trial published in Nature Medicine suggested it could reduce the incidence of Long COVID by 41% if taken early. However, it's not a magic pill; over 35% of people in that study dealt with gastrointestinal side effects. Similarly, Low-dose naltrexone (LDN) is being used off-label to fight fatigue, though it often brings sleep disturbances and headaches along for the ride.

The "Unknowns": Why is Finding a Cure So Hard?

The biggest hurdle isn't just the drugs; it's that we don't have a "blood test" for Long COVID. There are no validated biomarkers. Imagine trying to fix a car engine when you can't see the parts and don't have a diagnostic scanner. Vanderbilt researchers have pointed out that without these biomarkers, we can't tell who will respond to which treatment. This is especially problematic because the NIH has identified at least four distinct "endotypes" of Long COVID. This means the person with brain fog might need a completely different drug than the person with heart palpitations.

There are also competing theories about what's actually happening in the body. Some experts believe the virus is still hiding in "reservoirs" in the gut or brain (viral persistence). Others think the virus triggered an autoimmune response where the body attacks itself, or that the lining of the blood vessels is permanently damaged (endothelial dysfunction). If you treat for viral persistence but the real problem is autoimmunity, the drug won't work-or worse, it could make the inflammation worse.

We're also seeing a gap in safety data. Most of the drugs we're testing were approved for older adults with chronic illnesses like diabetes or rheumatoid arthritis. Long COVID often hits younger, previously healthy people. We cannot assume that a safety profile for an 80-year-old with arthritis applies to a 35-year-old with PASC. This uncertainty is why some clinicians, like Dr. Priscilla Hsue, warn that immunomodulatory drugs need extreme caution in patients who already have a dysregulated immune system.

Trial Failures and Future Bets

Not every trial is a success story. The BC007 trial, which aimed to neutralize autoantibodies, was suspended in March 2025 after it failed to beat the placebo. Even worse, the treatment group had a higher rate of infusion reactions. This serves as a stark reminder that the biological complexity of Long COVID is a graveyard for many promising therapies.

However, there are new directions. Researchers are now looking at GLP-1 receptor agonists, such as Tirzepatide (Mounjaro). Since these drugs help with metabolic dysregulation and potentially neuroinflammation, they might address the profound exhaustion and "brain fog" many patients experience. There's also a push toward physical interventions, like stellate ganglion blocks, though we lack large-scale safety data for this specific population.

On the cutting edge, a team from WEHI discovered a novel antiviral compound that worked in mice back in April 2025. While exciting, it's years away from human use. Toxicity studies are only just beginning in 2026, reminding us that the jump from a lab mouse to a human patient is a massive leap.

The Reality of Off-Label Use

Because official treatments are lagging, many patients are taking matters into their own hands. Data from the Body Politic support group shows that nearly 68% of members have tried an off-label medication. Metformin and LDN are the most popular choices. But here's the catch: over half of these people reported that the drugs didn't help, and 41% found that the side effects were actually worse than the symptoms they were trying to treat. This is the danger of the "patient-led" approach without clinical guidance-you might trade brain fog for chronic insomnia or severe stomach issues.

As we move toward 2027 and 2028, the hope is that the phase 3 results for Baricitinib and Metformin will finally provide the first FDA-approved path forward. Until then, the focus remains on managing symptoms and participating in structured trials rather than guessing with off-label prescriptions.

Next Steps for Patients and Caregivers

If you are currently managing Long COVID, the best path forward isn't found in a pharmacy, but in a specialized clinic. Look for providers who are part of the RECOVER network or affiliated with major research universities. If you're considering an off-label medication, ask your doctor specifically about the "safety signals" associated with your specific health history-especially if you have a history of blood clots or autoimmune issues.

For those struggling with sleep, keep an eye on the RECOVER-SLEEP trials. For those with severe metabolic fatigue, discuss the emerging research on GLP-1 agonists with your physician. Remember that because this is a multisystem condition, a combination of pacing, rehabilitative therapy, and targeted medication is usually more effective than any single "miracle drug."